A mid-term review of outcomes in previously untreated patients with advanced ALK-positive NSCLC found that lorlatinib, a third-generation inhibitor of ALK, had significantly longer PFS and more significant proportion of intracranial responses [120]. Here, ALK is linked to non-small cell lung carcinoma.